INT52441

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.21
First Reported 1995
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 10
Total Number 11
Disease Relevance 5.23
Pain Relevance 2.41

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (Ptger2) plasma membrane (Ptger2) signal transducer activity (Ptger2)
Anatomy Link Frequency
RAW 264 4
MDA-MB-468 2
MDA-MB-231 2
body 2
Ptger2 (Mus musculus)
Pain Link Frequency Relevance Heat
dexamethasone 2 99.84 Very High Very High Very High
COX2 15 98.52 Very High Very High Very High
cINOD 53 96.64 Very High Very High Very High
IPN 8 89.88 High High
bradykinin 6 84.32 Quite High
qutenza 100 82.68 Quite High
Inflammation 119 82.00 Quite High
cytokine 48 79.76 Quite High
Thermal hyperalgesia 30 79.68 Quite High
aspirin 1 77.12 Quite High
Disease Link Frequency Relevance Heat
Hemophilus Infection 89 100.00 Very High Very High Very High
Breast Cancer 135 99.68 Very High Very High Very High
INFLAMMATION 148 96.40 Very High Very High Very High
Obesity 122 96.08 Very High Very High Very High
Metabolic Syndrome 2 90.16 High High
Inflammatory Pain 8 89.88 High High
Reprotox - General 1 5 88.96 High High
Endometriosis (extended) 1 88.80 High High
Diabetes Mellitus 6 87.68 High High
Targeted Disruption 26 85.12 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In the presence of PGE2 or PGI2, the temperature threshold for TRPV1 activation was reduced below 35°C, so that temperatures near body temperature are sufficient to activate TRPV1.
Negative_regulation (reduced) of Localization (presence) of PGE2 in body
1) Confidence 0.21 Published 2005 Journal Mol Pain Section Abstract Doc Link PMC1074353 Disease Relevance 0.69 Pain Relevance 0.51
When calphostin C (Calp.C), a specific PKC inhibitor, was added to the pipette solution, the effect of PGE2 was almost completely inhibited (0.92 ± 0.15 fold increase, n = 10) (Figure 2F).
Negative_regulation (inhibited) of Localization (effect) of PGE2
2) Confidence 0.21 Published 2005 Journal Mol Pain Section Body Doc Link PMC1074353 Disease Relevance 0 Pain Relevance 0.16
By contrast with dexamethasone, which reduced PGE2 release together with a strong reduction of COX2 expression (protein and mRNA), non steroidal anti-inflammatory drugs (NSAIDs) reduced PGE2 synthesis without any effect at the COX2 mRNA level.
Negative_regulation (reduced) of Localization (release) of PGE2 associated with inflammation, cinod, cox2 and dexamethasone
3) Confidence 0.08 Published 1995 Journal Biochim. Biophys. Acta Section Abstract Doc Link 7766705 Disease Relevance 0.33 Pain Relevance 1.15
All doses of celecoxib significantly reduced PGE2 secretion by both cell lines (P < 0.01 for MDA-MB-231 and P = 0.03, 0.02 and 0.01 for MDA-MB-468 cells; Table 1), indicating that celecoxib is a potent inhibitor of COX-2 induced PGE2 production.


Negative_regulation (reduced) of Localization (secretion) of PGE2 in MDA-MB-468
4) Confidence 0.05 Published 2005 Journal Breast Cancer Res Section Body Doc Link PMC1175053 Disease Relevance 0.32 Pain Relevance 0
Regardless of COX-2 expression and regulation patterns, celecoxib treatment reduced PGE2 secretion by both cell lines (Table 1), but provision of exogenous PGE2 reversed celecoxib-induced growth inhibition in the MDA-MB-468 cells only, and not in the MDA-MB-231 cells (Fig. 5).
Negative_regulation (reduced) of Localization (secretion) of PGE2 in MDA-MB-231
5) Confidence 0.04 Published 2005 Journal Breast Cancer Res Section Body Doc Link PMC1175053 Disease Relevance 0.23 Pain Relevance 0.03
Because celecoxib caused growth inhibition in the two breast cancer cell lines and inhibited PGE2 secretion, we hypothesized that this growth inhibition was PGE2 dependent.
Negative_regulation (inhibited) of Localization (secretion) of PGE2 associated with breast cancer
6) Confidence 0.04 Published 2005 Journal Breast Cancer Res Section Body Doc Link PMC1175053 Disease Relevance 0.30 Pain Relevance 0
Moreover, PGE2 release by NTHi, also, was significantly reduced by both p38 MAPK inhibitors and NF-kappa B inhibitor.
Negative_regulation (reduced) of Localization (release) of PGE2 associated with hemophilus infection
7) Confidence 0.03 Published 2008 Journal Respir Res Section Body Doc Link PMC2270828 Disease Relevance 0.91 Pain Relevance 0.10
Consistent with our report, CO has been shown to down-regulate LPS-induced COX-2 expression and PGE2 secretion by inhibiting CCAAT/enhancer-binding protein (C/EBP) in LPS-treated RAW 264.7 cells [36].
Negative_regulation (regulate) of Localization (secretion) of PGE2 in RAW 264
8) Confidence 0.02 Published 2010 Journal J Neuroinflammation Section Body Doc Link PMC3002338 Disease Relevance 0.36 Pain Relevance 0.10
Consistent with our report, CO has been shown to down-regulate LPS-induced COX-2 expression and PGE2 secretion by inhibiting CCAAT/enhancer-binding protein (C/EBP) in LPS-treated RAW 264.7 cells [36].
Negative_regulation (down) of Localization (secretion) of PGE2 in RAW 264
9) Confidence 0.02 Published 2010 Journal J Neuroinflammation Section Body Doc Link PMC3002338 Disease Relevance 0.36 Pain Relevance 0.10
together with either curcumin or resveratrol, we were able to measure a dose-dependent reduction in secreted levels of IL-6 (Fig. 9) and PGE2 (Fig. 10).


Negative_regulation (reduction) of Localization (secreted) of PGE2
10) Confidence 0.02 Published 2008 Journal Nutr Metab (Lond) Section Body Doc Link PMC2441623 Disease Relevance 1.01 Pain Relevance 0.25
Celecoxib has been shown to inhibit the release of PGE2 or PGF2?
Negative_regulation (inhibit) of Localization (release) of PGE2
11) Confidence 0.01 Published 2007 Journal Breast Cancer Res Section Body Doc Link PMC2206712 Disease Relevance 0.72 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox